Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience

摘要

Dupilumab was recently approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD), for which current treatment options are limited [1]. Dupilumab binds to the IL-4Rα subunit and blocks the signaling of IL-4 and IL-13, thereby inhibiting the release of proinflammatory cytokines, chemokines, and IgE [2,3]. Although generally well-tolerated, high rates of unspecified conjunctivitis have been reported in patients on dupilumab [2-4].